Pfizer's COVID-19 Vaccine: What to Know
The duo's vaccine, known as BNT162b2, proved to be 90% effective after being tested on nearly 44,000 participants in its Phase III study. This is a significant milestone in the fight against a virus that has infected more than 50 million people around the globe, resulting in over 1.2 million deaths. FOX Business takes a look at the key data points investors and consumers should know, as well as reactions from business and political leaders.